Sartorius Stedim Biotech SA / Key word (s): Quarter Results/Forecast Sartorius Stedim Biotech publishes unaudited first quarter results for 2025 16-Apr-2025 / 07:00 CET/CEST ...

Sartorius Stedim Biotech SA (SDMHF) reports robust Q1 2025 results with significant growth in Bioprocess Solutions and ...

French biopharmaceutical company Sartorius Stedim Biotech has announced the opening of its new centre for bioprocessing innovation in Marlborough, Massachusetts, US. The centre encourages teamwork ...

Sartorius Stedim Biotech reported its first-quarter 2025 results, exceeding company-compiled consensus estimates. Sales and adjusted EBITDA increased in constant currency by 10.4% and 19.9% ...

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell ...

Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, has launched the single- use ultrafilter Sartocon® Slice 50. The new crossflow filter device is ...

Sales revenue at 745 million euros, up 10.4 percent in constant currencies 1 (reported: 11.7 percent) Sartorius Stedim Biotech, a leading partner to the biopharmaceutical industry, started the fiscal ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...